| Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide H Tran, MP Moazami, H Yang, D McKenna-Yasek, CL Douthwright, ... Nature medicine 28 (1), 117-124, 2022 | 144 | 2022 |
| Hybrid Aptamer‐Molecularly Imprinted Polymer (aptaMIP) Nanoparticles from Protein Recognition—A Trypsin Model MV Sullivan, O Clay, MP Moazami, JK Watts, NW Turner Macromolecular bioscience 21 (5), 2100002, 2021 | 41 | 2021 |
| Efficient gene silencing in brain tumors with hydrophobically modified siRNAs MF Osborn, AH Coles, D Golebiowski, D Echeverria, MP Moazami, ... Molecular cancer therapeutics 17 (6), 1251-1258, 2018 | 28 | 2018 |
| Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts M Shin, IL Chan, Y Cao, AM Gruntman, J Lee, J Sousa, TC Rodríguez, ... Nucleic Acids Research 50 (15), 8418-8430, 2022 | 27 | 2022 |
| Locked nucleic acid gapmers and conjugates potently silence ADAM33, an asthma-associated metalloprotease with nuclear-localized mRNA HM Pendergraff, PM Krishnamurthy, AJ Debacker, MP Moazami, ... Molecular Therapy Nucleic Acids 8, 158-168, 2017 | 26 | 2017 |
| Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system MP Moazami, JM Rembetsy-Brown, SL Sarli, HR McEachern, F Wang, ... Molecular Therapy 32 (12), 4401-4417, 2024 | 19 | 2024 |
| Potent mixed backbone antisense oligonucleotide safely suppresses expression of mutant c9orf72 transcripts and polydipeptides: First in human pilot study H Tran, MP Moazami, H Yang, D McKenna-Yasek, C Douthwright, C Pinto, ... Research Square, 2021 | 5 | 2021 |
| Progress toward an amplifiable metabolic label for DNA: Conversion of 4-thiothymidine (4sT) to 5-methyl-2′-deoxycytidine and synthesis of a 4sT phosphorodiamidate prodrug AK Hedger, ME Oomen, V Liu, MP Moazami, N Rhind, J Dekker, JK Watts Canadian Journal of Chemistry 96 (7), 636-645, 2018 | 3 | 2018 |
| RNase-H-mediated silencing in the CNS proves predictably nontrivial MP Moazami, MJA Wood Med 3 (11), 733-734, 2022 | 1 | 2022 |
| Targeting the mechanism of c-MPL exon-inclusion through antisense oligonucleotides yields a dominant negative isoform S Suzuki, RR Racine, NA Manalo, N Saini, C Odour, M Moazami, ... Blood 130, 383, 2017 | 1 | 2017 |
| Anti-c9orf72 oligonucleotides and related methods RH Brown Jr, JK Watts, H Tran, M Moazami US Patent App. 18/178,206, 2023 | | 2023 |
| Anti-C9ORF72 oligonucleotides and related methods RH Brown Jr, JK Watts, H Tran, M Moazami US Patent 11,629,347, 2023 | | 2023 |
| Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System [preprint] MP Moazami, JM Rembetsy-Brown, F Wang, PM Krishnamurthy, A Weiss, ... | | 2021 |
| Potent Mixed Backbone Antisense Oligonucleotide Safety Suppressed Expression of Mutant C9ORF72 Transcripts and Polypeptides: First in Human Pilot Study R Brown, H Tran, M Moazami, H Yang, D McKenna-Yasek, C Douthwright, ... | | 2021 |
| Synthesis, biodistribution and efficacy of monomeric and multimeric antisense oligonucleotides in visceral tissue and the central nervous system M Moazami University of Southampton, 2018 | | 2018 |
| Locked Nucleic Acid gapmers and conjugates induce potent silencing of ADAM33, an asthma-associated metalloprotease with nuclear-localized mRNA HM Pendergraff, PM Krishnamurthy, AJ Debacker, M Moazami, ... Molecular Therapy: Nucleic Acid, 2017 | | 2017 |
| Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA VK Sharma, L Niitsoo, Y Yu, YN Tan, HM Haitchi, JK Watts Molecular Therapy 159, 2017 | | 2017 |
